Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies.
Yong WP, Goh BC, Soo RA, Toh HC, Ethirajulu K, Wood J, Novotny-Diermayr V, Lee SC, Yeo WL, Chan D, Lim D, Seah E, Lim R, Zhu J. Yong WP, et al. Among authors: lim r, lim d. Ann Oncol. 2011 Nov;22(11):2516-2522. doi: 10.1093/annonc/mdq784. Epub 2011 Mar 8. Ann Oncol. 2011. PMID: 21385886 Free article. Clinical Trial.
Clinical and molecular characteristics of hereditary non-polyposis colorectal cancer families in Southeast Asia.
Lee SC, Guo JY, Lim R, Soo R, Koay E, Salto-Tellez M, Leong A, Goh BC. Lee SC, et al. Among authors: lim r. Clin Genet. 2005 Aug;68(2):137-45. doi: 10.1111/j.1399-0004.2005.00469.x. Clin Genet. 2005. PMID: 15996210
Lee S-C, Guo J-Y, Lim R, Soo R, Koay E, Salto-Tellez M, Leong A, Goh B-C. Clinical and molecular characteristics of hereditary non-polyposis colorectal cancer families in Southeast Asia. ...
Lee S-C, Guo J-Y, Lim R, Soo R, Koay E, Salto-Tellez M, Leong A, Goh B-C. Clinical and molecular characteristics of her …
Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG).
Yeo W, Boyer M, Chung HC, Ong SY, Lim R, Zee B, Ma B, Lam KC, Mo FK, Ng EK, Ho R, Clarke S, Roh JK, Beale P, Rha SY, Jeung HC, Soo R, Goh BC, Chan AT; Cancer Therapeutics Research Group (CTRG). Yeo W, et al. Among authors: lim r. Cancer Chemother Pharmacol. 2007 Feb;59(3):295-300. doi: 10.1007/s00280-006-0270-1. Epub 2006 Jun 17. Cancer Chemother Pharmacol. 2007. PMID: 16783579 Clinical Trial.
PharmGKB update: II. CYP3A5, cytochrome P450, family 3, subfamily A, polypeptide 5.
Schuetz EG, Relling MV, Kishi S, Yang W, Das S, Chen P, Cook EH, Rosner GL, Pui CH, Blanco JG, Edick MJ, Hancock ML, Winick NJ, Dervieux T, Amylon MD, Bash RO, Behm FG, Camitta BM, Raimondi SC, Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J, Lim R, Lim HL, Ong AB, Lee HS, Kuehl P, Zhang J, Lin Y, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS. Schuetz EG, et al. Among authors: lim r, lim hl. Pharmacol Rev. 2004 Jun;56(2):159. doi: 10.1124/pr.56.2.1. Pharmacol Rev. 2004. PMID: 15169924 No abstract available.
2,178 results